| HOME >> MEDICINE >> TECHNOLOGY |
5,5424,400Changes in operating assets and liabilities:Accounts receivable
1,943(840)Inventory
(5,501)(5,882)Prepaid expenses and other current assets
(3,538)(1,232)Other non-current assets
(768)(23)Accounts payable and other current liabilities
(1,600)(2,462)Accrued compensation
(3,071)(2,175)Deferred revenue
251677Net cash used in operating activities
(8,352)(2,815)Cash flows from investing activities:Capital expenditures
(4,587)(3,543)Payments for technology licenses
-(1,000)Cost of acquisitions, net
(16,992)(296)Proceeds from the sale of fixed assets
-20Net cash used in investing activities
(21,579)(4,819)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options
19,4098,711Principal payment of notes payable
-(345)Net cash provided by financing activities
19,4098,366Effect of exchange rate change on cash
(495)190Net increase (decrease) in cash and cash equivalents
(11,017)922Cash and cash equivalents at beginning of period
115,00879,538Cash and cash equivalents at end of period
$
3,991$
80,460 CEPHEID
RECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)
Three Months Ended
March 31,20122011Cost of product sales$
35,608$
25,310 Stock compensation expense(635)(499) Amortization of purchased intangible assets(333)(344)Non-GAAP measure of cost of product sales$
34,640$
24,467Gross margin on product sales per GAAP53%56%Gross margin on product sales per Non-GAAP54%58%Operating expenses$
47,665$
32,651 Stock compensation expense(4,863)(3,901) Amortization of purchased intangible assets(316)(108)Non-GAAP measure of operatin
'/>"/>
| SOURCE Cepheid Copyright©2010 PR Newswire. All rights reserved |